Industries Answer Call-to-Action with Expertise and Resources to Mitigate Global Pandemic CAMPBELL, Calif.–(BUSINESS WIRE)–#covidcure–The EndPandemic National Data Consortium announced today that it has received commitments from six leading life sciences and information technology companies to join the Consortium, the formation of which was announced on March 30, 2020. The companies will work together to achieve the singular goal of integrating data from all ongoing and future clinical studies to dramatically accelerate analysis on COVID-19 and SARS-CoV-2 research in order to reduce the time to find a cure by up to 50 percent.     “The new EndPandemic National Data Consortium partners are to be applauded for the speed with which they answered the call to protect and ensure public health,” said Kenneth Massey, Pharm.D., Chief Life Sciences Ocer of Saama Technologies. “The integrated database developed by the Consortium will be a comprehensive, collective platform that will inform and accelerate medical […]

  Industries Answer Call-to-Action with Expertise and Resources to Mitigate Global Pandemic   The EndPandemic National Data Consortium announced today that it has received commitments from six leading life sciences and information technology companies to join the Consortium, the formation of which was announced on March 30, 2020. The companies will work together to achieve the singular goal of integrating data from all ongoing and future clinical studies to dramatically accelerate analysis on COVID-19 and SARS-CoV-2 research in order to reduce the time to find a cure by up to 50 percent. “The new EndPandemic National Data Consortium partners are to be applauded for the speed with which they answered the call to protect and ensure public health,” said Kenneth Massey, Pharm.D., Chief Life Sciences Officer of Saama Technologies. “The integrated database developed by the Consortium will be a comprehensive, collective platform that will inform and accelerate medical experts’ abilities to arrive […]

Industries Answer Call-to-Action with Expertise and Resources to Mitigate Global Pandemic   CAMPBELL, Calif.–(BUSINESS WIRE)–#covidcure–The EndPandemic National Data Consortium announced today that it has received commitments from six leading life sciences and information technology companies to join the Consortium, the formation of which was announced on March 30, 2020. The companies will work together to achieve the singular goal of integrating data from all ongoing and future clinical studies to dramatically accelerate analysis on COVID-19 and SARS-CoV-2 research in order to reduce the time to find a cure by up to 50 percent.     “The new EndPandemic National Data Consortium partners are to be applauded for the speed with which they answered the call to protect and ensure public health,” said Kenneth Massey, Pharm.D., Chief Life Sciences Officer of Saama Technologies. “The integrated database developed by the Consortium will be a comprehensive, collective platform that will inform and accelerate […]

iNDX.Ai, a Bio-IT company based out of Silicon Valley focused at developing and providing innovative software products to guide translational research and enable better outcome for cancer cure has been recognized as “Top 10 Bioinformatics Solution Providers – 2019” by CIO Applications Magazine In continuation with winning recognition for many of its Bio-IT innovations, iNDX.Ai for the second time in the year 2019 has been recognized with this . The distinguished team at CIO Applications inclusive of top industry analysts and CIOs recognize top 10 bioinformatics solution providers every year for their innovative contribution to the field by studying competence and capabilities. This year iNDX.Ai has been recognized as one of the Top 10 in this list of bioinformatics solution providers for its portfolio of solutions focused at aiding researchers with multi-omics fueled efficient cancer treatment methods in October 2019. iCORE, a cloud-based application developed by iNDX.Ai is a solution […]

Sep 16, 2019 Compliance with HIPAA. Cupertino, CA – May 19, 2019,  iNDX Technology, Inc. d/b/a iNDX.Ai, the leader for managing Immuno-Oncology clinical trials and translational research.  iNDX.Ai helps scientists, researchers, and principal investigators find a cure for cancer by combining innovations in science with innovations in technology. We provide a SaaS-based model that provides deeper insights, accelerates scientific discovery, and enable better outcomes , has announced compliance with the Health Insurance Portability and Accountability Act of 1996. The Privacy Rule or Standards for the Privacy of Individually Identifiable Health Information, issued by the Department of Health and Human Services implements the requirement of the Health Insurance Portability and Accountability Act of 1996. It establishes a set of national standards for the protection of certain health information. The standards address the use and disclosure of individuals’ health information — called protected health information (PHI) — by organizations subject to the Privacy […]

Cupertino, CA – July 7, 2019 In a major regulatory compliance achievement, iNDX.Ai has now tailored its SaaS-based iCore V4.0TM informatics platform to include compatibility of its documentation management suite with FDA’s Title 21 CFR Part 11 regulations. This means that iNDX.Ai’s clients can have unprecedented control and assurance when managing electronic records and electronic signatures (ERES) within the iCore V4.0 platform. So how exactly does this integration benefit iNDX.Ai’s clients? About 21 CFR part 11 compliance The Federal government codifies regulations for Food and Drugs industries under Section 21 of the Code of Federal Regulations (CFR). The clinical trial stakeholder that utilize electronic records and electronic signatures (ERES) are required to follow specific formats to be in compliance with the guidelines outlined within part 11 of this Section.  FDA mandates this to ensure authenticity, confidentiality, and trustworthiness of electronic documents that are submitted to the FDA. Non-compliance from these […]

Cupertino, CA – July 9, 2019 iNDX.Ai is in the process of upgrading its flagship product with promising value-added features. Following the incorporation of features that allow iCoreV4.0 to be compatible with the FDA mandated 21 CFR Part 11, the California based start-up has also upgraded its flagship product to include compatibility with European Union’s (EU) General Data Protection Regulation (GDPR).  These two new features will ensure regulatory compliance across geographical boundaries and are of immense value to clinical trial stakeholders who use this platform. The incorporation of GDPR compatibility will ensure that clinical trial stakeholders who deal with sensitive and confidential electronic health records (EHRs), patient data,  and other forms of sensitive information are in compliance with European Union’s strict GDPR policies on data privacy.  About GDPR GDPR was developed by the EU to safeguard the security and privacy of data of subjects within the EU. However, U.S. biopharma […]

Silicon Valley-based start-up iNDX Technology has been awarded the prestigious title of  “Top 10 Analytics Solution Providers – 2019” by Pharma Tech Outlook – a leading online magazine that engages industry experts and peers to facilitate exchange of information on latest  tech developments in pharma sector Cupertino, California, May 31st, 2019 In a major recognition of its work, Silicon Valley-based start-up iNDX Technology has been awarded the prestigious title of  “Top 10 Analytics Solution Providers – 2019” by Pharma Tech Outlook. Pharma Tech Outlook publishes a list of “Top 10 Analytics Solution Providers” annually, recognizing the efforts of ingenious solution providers who leverage creative data analytics strategies to overcome pharma-related hurdles. This year iNDX.Ai clinched a spot on this prestigious list published in “pharma analytics special” published on April 19th this year. Mohan Uttarwar, the company’s CEO expressed his gratitude to Pharma Tech Outlook for this recognition and thanked his […]

In a major market-positioning endeavour, Silicon valley-based start-up iNDX Technology has rechristened itself as “iNDX.Ai” – highlighting the importance of artificial intelligence (AI) which is the predominant technology driving their flagship informatics platform iCore V4.0TM.  Artificial intelligence, like the blockchain technology and personalized medicine, has become the next poster child of tech pundits – who are betting heavily on the pivotal and disruptive role of this technology in healthcare.  According to a recent report by Accenture’s, AI-inspired clinical technologies will enjoy tremendous growth and dominate technologies such as dosage error reductions platforms ($16 billion), clinical trial participant identifiers ($13 billion), preliminary diagnosis platforms ($5 billion), automated image diagnosis software ($3 billion). These trends point towards a demand for powerful AI tools that can interpret the constant inpouring of data from the rapidly mushrooming crop of pharma stakeholders, including those that are conducting of immuno-oncology trials. Artificial intelligence (AI)-based strategies are now being touted […]

The iCore V4 platform  launch under Indx.Ai brand is ideally suited to significantly increase the speed of deriving clinical and therapeutic insights from multi-omics data for complex I/O trials We are excited to announce the launch of our newest version of the iCore platform that supports our mission of helping scientists and clinicians find cure for cancer by combining innovations in science and technologies (AI/ML/NLP) – an approach we believe provides better insights and generates better outcomes. iCore offers cloud-based suite of applications that helps you aggregate, organize, analyze, visualize, interrogate and correlate the clinical, exploratory, imaging and safety data that is amassed during early translational research. “We have leveraged our  experience of working with Parker Institute for Cancer Immunotherapy, and its affiliates such as –  University of Texas MD Anderson Cancer Center, UCLA, UPenn, Stanford, and the Memorial Sloan Kettering Cancer Center,  to develop iCore platform and we are […]